These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
91 related items for PubMed ID: 18336911
1. Transcriptional silencing of RFXAP in MHC class II-deficiency. van Eggermond MC, Tezcan I, Heemskerk MH, van den Elsen PJ. Mol Immunol; 2008 May; 45(10):2920-8. PubMed ID: 18336911 [Abstract] [Full Text] [Related]
8. Novel mutations within the RFX-B gene and partial rescue of MHC and related genes through exogenous class II transactivator in RFX-B-deficient cells. Nagarajan UM, Peijnenburg A, Gobin SJ, Boss JM, van den elsen PJ. J Immunol; 2000 Apr 01; 164(7):3666-74. PubMed ID: 10725724 [Abstract] [Full Text] [Related]
10. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation. Li D, Qian L, Chen C, Shi M, Yu M, Hu M, Song L, Shen B, Guo N. J Immunol; 2009 Feb 15; 182(4):1799-809. PubMed ID: 19201831 [Abstract] [Full Text] [Related]
12. Molecular genetics of the Bare lymphocyte syndrome. Masternak K, Muhlethaler-Mottet A, Villard J, Peretti M, Reith W. Rev Immunogenet; 2000 Feb 15; 2(2):267-82. PubMed ID: 11258423 [Abstract] [Full Text] [Related]
13. Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency. Villard J, Lisowska-Grospierre B, van den Elsen P, Fischer A, Reith W, Mach B. N Engl J Med; 1997 Sep 11; 337(11):748-53. PubMed ID: 9287230 [Abstract] [Full Text] [Related]
14. Type III bare lymphocyte syndrome associated with a novel RFXAP mutation: a case report. Gokturk B, Artac H, van Eggermond MJ, van den Elsen P, Reisli İ. Int J Immunogenet; 2012 Aug 11; 39(4):362-4. PubMed ID: 22390233 [Abstract] [Full Text] [Related]
15. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival. Souwer Y, Chamuleau ME, van de Loosdrecht AA, Tolosa E, Jorritsma T, Muris JJ, Dinnissen-van Poppel MJ, Snel SN, van de Corput L, Ossenkoppele GJ, Meijer CJ, Neefjes JJ, Marieke van Ham S. Br J Haematol; 2009 May 11; 145(3):334-43. PubMed ID: 19245431 [Abstract] [Full Text] [Related]
16. Genetic and epigenetic control of the major histocompatibility complex class Ib gene HLA-G in trophoblast cell lines. Holling TM, Bergevoet MW, Wierda RJ, van Eggermond MC, van den Elsen PJ. Ann N Y Acad Sci; 2009 Sep 11; 1173():538-44. PubMed ID: 19758196 [Abstract] [Full Text] [Related]
17. The 752delG26 mutation in the RFXANK gene associated with major histocompatibility complex class II deficiency: evidence for a founder effect in the Moroccan population. Naamane H, El Maataoui O, Ailal F, Barakat A, Bennani S, Najib J, Hassar M, Saile R, Bousfiha AA. Eur J Pediatr; 2010 Sep 11; 169(9):1069-74. PubMed ID: 20414676 [Abstract] [Full Text] [Related]
18. MHC class II deficiency: definition of a new complementation group. Villard J, Mach B, Reith W. Immunobiology; 1997 Dec 11; 198(1-3):264-72. PubMed ID: 9442397 [Abstract] [Full Text] [Related]